Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salivary α-Amylase as a Non-Invasive Biomarker of PRF-Enhanced Wound Healing After Third Molar Surgery
NCT07600619Completed
- Sponsor
- Hasanuddin University
- Start
- May 2024
- Primary completion
- Nov 2024
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial of platelet rich fibrin in Impacted Mandibular Third Molar (IM3M) (2 arms), sponsored by Hasanuddin University. Primary endpoint: Mean Salivary α-Amylase Activity at Day 7. Started May 2024; status: completed.
02
Drugs
platelet rich fibrin
03
Conditions
Impacted Mandibular Third Molar (IM3M)
Beyond the preview
Go deeper on NCT07600619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600619.